undamentalytics Newsletter
Sign in

Sellas Life Sciences Group, Inc. insider trading

Every open-market purchase and sale by Sellas Life Sciences Group, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $100,806 1 trade by 1 insider 3 months later: median +149.3% (+145.5% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Sellas Life Sciences Group, Inc.’s insiders pay?

From March 30, 2010 to November 21, 2025, 17 insiders reported 6 open-market purchases and 23 sales not made under a pre-set plan in Sellas Life Sciences Group, Inc. After sales, the shares moved −78.2% against the index over 12 months (a negative figure means selling was the right call).

InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Cytrx Corp 10% owner 0 — — 3 — December 23, 2010
Hillsberg Sanford Director 0 — — 3 −87.2% (1) January 31, 2014
Nisi Rudolph Director 1 — — 2 −87.2% (1) February 13, 2014
Stergiou Angelos M. President and CEO 0 — — 3 −46.4% (1) December 5, 2022
Chin Richard Director 0 — — 2 — February 13, 2014
Galliker Stephen S Director 0 — — 2 — February 5, 2014
Kalin Katherine Bach Director 2 — — 0 — November 21, 2025
Kriegsman Steven A Director 0 — — 2 −87.2% (1) April 9, 2014
Ahn Mark J President & CEO 0 — — 1 −83.3% (1) January 29, 2014
Beerman Noah D CEO and President 1 — — 0 — July 12, 2010
Dunlap Ryan Former Chief Financial Officer 0 — — 1 — June 7, 2016
Gerber Sander 10% owner 0 — — 1 — February 10, 2017
Samarsky Dmitry VP, Technology Development 0 — — 1 — April 2, 2010
Schwartz Mark W. EVP & Chief Operating Officer 0 — — 1 — January 31, 2014
Van Nostrand Robert L Director 1 — — 0 — June 13, 2025
Varanasi Ramani VP Business Development 0 — — 1 — July 21, 2010
Wasman Jane Director 1 — — 0 — June 2, 2025

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Sellas Life Sciences Group, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Sellas Life Sciences Group, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 1 selling crowd, −55.9%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
January 31, 20144 selling−59.7%−55.9%−83.7%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Sellas Life Sciences Group, Inc. · Funds · Politicians